Journal article

Risk of Developing Prostate Cancer in the Future: Overview of Prognostic Biomarkers

Neil E Fleshner, Nathan Lawrentschuk

Urology | ELSEVIER SCIENCE INC | Published : 2009

University of Melbourne Researchers


Funding Acknowledgements

N. E, Fleshner serves as a consultant to AstraZeneca, Gk-coSmithKline, Merck, Sanofi-Aventis, Novartis, and Pfizer; he has received grant support for clinical trials from AstTaZeneca, GlaxoSmithKline, and Sanofi-Avenris. N. I.Awrentschuk has no conflicts to report.